IIQ 2.65% 58.0¢ inoviq ltd

Ann: Outstanding SubB2M Ovarian Cancer Test Data, page-395

  1. 2,059 Posts.
    lightbulb Created with Sketch. 343
    The title of that slide is: Potential Game Changer.The announcement on Thursday was validation of the results:
    BARD1’s SubB2M technology showing 100%specificity and sensitivity for detection of all stages of ovarian cancer.
    Thus, the Potential Game Changer is now confirmed and de-risked. That's the difference.
    HUGE NEWS!
 
watchlist Created with Sketch. Add IIQ (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.